AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04562428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiang Sha Liu Jun Zi Decoction dry powder
Description: the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei
Study NCT04562428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XSLJZ Placebo
Description: XSLJZ Placebo
Study NCT03254589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: See arm descriptions
Study NCT03254589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: See arm description
Study NCT03254589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other DMARDs
Description: See arm
Study NCT03965390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral education
Description: Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health
Study NCT01136980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIF Transoral Fundoplication
Description: A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
Study NCT01136980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham placebo procedure
Description: The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
Study NCT02118441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Radial Artery Catheter Insertion
Study NCT02118441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Palpation-guided Radial Artery Catheter insertion
Study NCT01495806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucomannan
Description: 2 x 5g
Study NCT01495806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: glucose 5 g
Study NCT02699424 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External radiation therapy
Study NCT02336529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT02336529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study NCT02876549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
Study NCT02876549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine 0.25 mg/kg/day
Description: 0.25 mg/kg/day for 14 days
Study NCT02876549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine 0.75 mg/kg weekly
Description: 0.75 mg/kg weekly for eight weeks
Study NCT01610934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
Study NCT01610934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
Study NCT02259335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal CO2 removal device
Description: A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
Study NCT00354978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m\^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m\^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m\^2 injection.
Study NCT00354978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle.
Study NCT00354978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
Study NCT00354978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2 by vein over 90 minutes on Day 1 of 14 day cycle.
Study NCT01079052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Tablets
Study NCT01079052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Tablets
Study NCT05504785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DexCom G6 continuous glucose monitor
Description: Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
Study NCT02194478 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meditation
Description: 30 minute, 8 week meditation
Study NCT03176706 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: this is a completely observational study, NO INTERVENTION
Study NCT02784691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feeligreen patch
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: aprepitant capsules
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: aprepitant capsules
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: ondansetron IV preparation
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: ondansetron IV preparation
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone tablets
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone tablets
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to aprepitant
Description: Matching placebo to aprepitant capsules
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to dexamethasone
Description: Matching placebo to dexamethasone tablets
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to dexamethasone
Description: Matching placebo to dexamethasone tablets
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue medication
Description: Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
Study NCT00080444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rescue medication
Description: Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
Study NCT03843554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Oral Hygiene
Description: Standard of care oral hygiene- weekly oral care visits with soft-bristled toothbrushing.
Study NCT03843554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral mucosal deterging and dental prophylaxis
Description: Subjects will receive a professional dental prophylaxis including periodontal surface debridement \[a light-touch, gentle form of instrumentation performed with an ultrasonic instrument to promote plaque removal, to facilitate biofilm disruption and endotoxin flushing, but yet with the preservation of the periodontal cementum\] and deterging of the oral mucosal surfaces.
Study NCT03714152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: 5 mg or 25 mg tablets
Study NCT03714152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABI-H2158
Description: Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
Study NCT02169427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC
Description: The drug substance of 100 mg OPC was administered as 1 capsule.
Study NCT04002492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bodyweight training
Description: Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
Study NCT00214201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitor withdrawal
Description: stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
Study NCT03944317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine
Description: SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
Study NCT03944317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
Study NCT00842751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: First Intervention (7 days)
Description: Acyline 300mcg/kg subcutaneous (days 1, 15 \& 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
Study NCT00842751 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: First Washout (7 days)
Description: Washout of 7 days between each of the 3 treatment arms
Study NCT00842751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Intervention (7 days)
Description: Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
Study NCT00842751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Third Intervention (7 days)
Description: Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
Study NCT00842751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second wash-out period
Description: Washout of 7 days between each of the 3 treatment arms
Study NCT00846092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warp 10 LED Device
Description: Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
Study NCT00846092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared light (NIR)
Description: * Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~* Treatments involve application of the LED-generated light for 80 seconds, twice daily.
Study NCT03843840 — intervention group
Intervention type: DEVICE
Intervention: Combined Coaxial Optical Coherence Tomography
Description: Taking images of the retina with two wavelengths
Study NCT00093704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib + ganciclovir
Description: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
Study NCT00463567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
Study NCT00463567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol (12 µg b.i.d.)
Description: Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
Study NCT00463567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium (18 µg o.d.)
Description: Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
Study NCT00463567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Indacaterol
Description: In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
Study NCT00463567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
Study NCT00463567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Indacaterol
Description: In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
Study NCT00463567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Formoterol
Description: In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
Study NCT00463567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Formoterol
Description: In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
Study NCT02721472 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: micro- and macro-circulatory vascular remodelling measures not practice in routine care
Description: Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
Study NCT02721472 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological measures not practice in routine care
Description: Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
Study NCT01794767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,9% NaCl flush
Description: Normal Saline solution
Study NCT01794767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin 50U/ml
Description: Heparin solution
Study NCT04096599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol toothpaste
Description: At-home preventive measures + xylitol-containing (25%) toothpaste
Study NCT04096599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: At-home preventive measures + fluoride (1000 ppm F) toothpaste
Study NCT05497999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Outreach
Description: The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral.
Study NCT05497999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Proactive Outreach
Description: Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
Study NCT01398709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow rewarming strategy
Description: Rewarming rate:0.24 degrees C/min.
Study NCT01398709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast rewarming strategy
Description: Rewarming rate:0.5 degrees C/min.
Study NCT03202771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Biofeedback Therapy
Description: Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.
Study NCT03202771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office Biofeedback Therapy
Description: A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. Biofeedback Therapy (BT) will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
Study NCT03877328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiotechCoachForAll
Description: A group of thirty subjects diagnosed with heart failure (HF) of any etiology undergo an experimental procedure in the following order: resting-state (eyes-closed), passively viewing thirty two agents which are grouped with respect to different appearance characteristics and passively viewing combinations of virtual agents. During the experiment, brain activity, heart rate, skin conductance, temperature and eye-gaze biosignals are collected by means of electroencephalography, Empatica E4 and Gazepoint. Subsequently, a prospective cohort study is performed in a subgroup of ten participants which undergo a three additive stage procedure. Stage 1, a wearable monitoring device (Wavelet Health) is given in order to provide objective information on the patient's activity. Stage 2, the FitForAll physical exercise program is introduced. Stage 3, introduces the coaching aspects, where personalized recommendations and suggestions are delivered through home surfaces' projection.
Study NCT02532738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Routine Treatment of CD
Description: The Drug including 6MP, AZA, infliximab and thalidomide
Study NCT02532738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Treatment of CD
Description: The Drug including 6MP, AZA, infliximab and thalidomide
Study NCT02532738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC treatment 01
Description: Injection of 3×10E6/kg of MSC
Study NCT02532738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC treatment 02
Description: Injection of 6×10E6/kg of MSC
Study NCT02532738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NS
Description: Injection of NS
Study NCT03868813 — intervention group
Intervention type: BEHAVIORAL
Intervention: Semi-structured Interview
Description: One-on-one semi-structured interviews
Study NCT01875406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic exercises